Clazosentan
97%
- Product Code: 163709
CAS:
180384-56-9
| Molecular Weight: | 577.57 g./mol | Molecular Formula: | C₂₅H₂₃N₉O₆S |
|---|---|---|---|
| EC Number: | MDL Number: | MFCD20040418 | |
| Melting Point: | Boiling Point: | 754.5±70.0 °C(Predicted) | |
| Density: | 1.485±0.06 g/cm3(Predicted) | Storage Condition: | 2-8°C, sealed, dry |
Product Description:
Clazosentan is primarily used to reduce the incidence of cerebral vasospasm following aneurysmal subarachnoid hemorrhage. It acts as an endothelin receptor antagonist, specifically targeting the ETA receptor, which plays a key role in vasoconstriction. By blocking this receptor, clazosentan helps maintain cerebral blood flow, potentially preventing delayed ischemic neurological deficits. It is administered intravenously in critical care settings, especially in neurointensive units, to improve outcomes in patients recovering from ruptured brain aneurysms. Clinical studies have shown its effectiveness in reducing vasospasm-related complications, though its impact on long-term functional recovery is still under investigation.
Product Specification:
| Test | Specification |
|---|---|
| Appearance | Off-White to Light Yellow Powder or Crystals |
| Purity | 96.5-100% |
| Infrared Spectrum | Conforms to Structure |
| NMR | Conforms to Structure |
Sizes / Availability / Pricing:
| Size | Availability | Price | Quantity |
|---|---|---|---|
| 5mg | 10-20 days | ฿21,780.00 |
+
-
|
| 25mg | 10-20 days | ฿83,930.00 |
+
-
|
| 10mg | 10-20 days | ฿38,280.00 |
+
-
|
Clazosentan
Clazosentan is primarily used to reduce the incidence of cerebral vasospasm following aneurysmal subarachnoid hemorrhage. It acts as an endothelin receptor antagonist, specifically targeting the ETA receptor, which plays a key role in vasoconstriction. By blocking this receptor, clazosentan helps maintain cerebral blood flow, potentially preventing delayed ischemic neurological deficits. It is administered intravenously in critical care settings, especially in neurointensive units, to improve outcomes in patients recovering from ruptured brain aneurysms. Clinical studies have shown its effectiveness in reducing vasospasm-related complications, though its impact on long-term functional recovery is still under investigation.
| Mechanism | - |
| Appearance | - |
| Longevity | - |
| Strength | - |
| Storage | - |
| Shelf Life | - |
| Allergen(s) | - |
| Dosage (Range) | - |
| Recommended Dosage | - |
| Dosage (Per Day) | - |
| Recommended Dosage (Per Day) | - |
| Mix Method | - |
| Heat Resistance | - |
| Stable in pH range | - |
| Solubility | - |
| Product Types | - |
| INCI | - |
Purchase History for
Loading purchase history...
Cart
No products
Subtotal:
฿0.00
฿0.00
Total :